Table 2.

Descriptive statistics of prostate cancer patients according to type of LHRH agonist (n=65)

Brand of LHRH (median and IQR)	Age	PSA (ug/L) at time of testosterone	Serum testosterone (nmol/L)	Duration of LHRH use (months)	Disease status*
					†1: 44.44%
					2: 16.66%
Eligard (n=18)	72.5 (68.25–80)	0.03 (0–1.9625)	1.2 (0.95–1.55)	48 (24.25–81)	3: 0%
					4: 33.33%
					5: 5.55%
					1: 26%, 2 (34%), 3 (6%), 4 (30%), 5 (4%)
					2:
Lupron (n=50)	78 (71.25–83)	2.695 (0.51–10.01	1.3 (1–1.8)		3:
					4:
					5:
Suprefact (n=19)	76 (71–83)	0.25 (0–3.2)	1.5 (1.05–1.6)	108 (78–132)	1 (36.84%), 2 (26.315%), 3 (0%), 4 (26.315%), 5 (10.526%)
Trelstar (n=19)	67 (66–76)	0 (0–0.06)	1.1 (0.7–1.2)	12 (12–24)	1 (40%), 2 (20%), 3 (0%), 4 (20%) 5 (20%)
Zoladex (n=73)	74 (67–80)	0.3 (0–15.79)	1.3 (0–1.8)	48 (24–108)	1 (18.6%), 2 (34.3%), 3 (11.4%), 4 (30%), 5 (5.7%)

^†1: Biochemical recurrence; 2: metastases; 3: castrate-resistant prostate cancer; 4: locally advanced; 5: not known.

IQR: interquartile range; HRH: luteinizing hormone releasing-hormone; PSA: prostate-specific antigen.

^*Values are percentages of total in each group.